9 December 2020
EMA/670383/2020
EMEA/H/C/004098

Public statement

Truberzi

Withdrawal of the marketing authorisation in the European Union

On 18 December 2020 the European Commission withdrew the marketing authorisation for Truberzi (eluxadoline) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Allergan Pharmaceuticals International Limited, which notified the European Commission of its decision to discontinue the marketing of the product for commercial reasons.

Truberzi was granted marketing authorisation in the EU on 19 September 2016 for the treatment of irritable bowel syndrome with diarrhoea. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2018.

The European Public Assessment Report (EPAR) for Truberzi will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union